User: Guest  Login
Document type:
Journal Article; Article
Author(s):
Lewczuk, P; Kamrowski-Kruck, H; Peters, O; Heuser, I; Jessen, F; Popp, J; Bürger, K; Hampel, H; Frölich, L; Wolf, S; Prinz, B; Jahn, H; Luckhaus, C; Perneczky, R; Hüll, M; Schröder, J; Kessler, H; Pantel, J; Gertz, HJ; Klafki, HW; Kölsch, H; Reulbach, U; Esselmann, H; Maler, JM; Bibl, M; Kornhuber, J; Wiltfang, J
Title:
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
Abstract:
In this report, we present the results of a multicenter study to test analytic and diagnostic performance of soluble forms of amyloid precursor proteins alpha and beta (sAPP alpha and sAPP beta) in the cerebrospinal fluid (CSF) of patients with different forms of dementing conditions. CSF samples were collected from 188 patients with early dementia (mini-mental state examination >or=20 in majority of cases) and mild cognitive impairment (MCI) in 12 gerontopsychiatric centers, and the clinical diagnoses were supported by neurochemical dementia diagnostic (NDD) tools: CSF amyloid beta peptides, Tau and phospho-Tau. sAPP alpha and sAPP beta were measured with multiplexing method based on electrochemiluminescence. sAPP alpha and sAPP beta CSF concentrations correlated with each other with very high correlation ratio (R=0.96, P<0.001). We observed highly significantly increased sAPP alpha and sAPP beta CSF concentrations in patients with NDD characteristic for Alzheimer's disease (AD) compared to those with NDD negative results. sAPP alpha and sAPP beta highly significantly separated patients with AD, whose diagnosis was supported by NDD findings (sAPP alpha: cutoff, 117.4 ng ml(-1), sensitivity, 68%, specificity, 85%, P<0.001; sAPP beta: cutoff, 181.8 ng ml(-1), sensitivity, 75%, specificity, 85%, P<0.001), from the patients clinically assessed as having other dementias and supported by NDD untypical for AD. We conclude sAPP alpha and sAPP beta might be regarded as novel promising biomarkers supporting the clinical diagnosis of AD.
Journal title abbreviation:
Mol Psychiatry
Year:
2010
Journal volume:
15
Journal issue:
2
Pages contribution:
138-45
Language:
eng
Fulltext / DOI:
doi:10.1038/mp.2008.84
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/18663368
Print-ISSN:
1359-4184
TUM Institution:
Klinik und Poliklinik für Psychiatrie und Psychotherapie
 BibTeX